Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System

<div>Heatmap of signal strength for different PPIs correlated with different digestive tract cancers (ROR lower bound of 95% CI). PPIs, proton pump inhibitors; GNM, gastric neoplasms malignant; PNM, pancreatic neoplasms malignant; BDNM, bile duct neoplasms malignant; SINM, small intestinal neoplasms malignant; ONM, oesophageal neoplasms malignant; CNM, colorectal neoplasms malignant; ACNM, anal canal neoplasms malignant; GBNM, gallbladder neoplasms malignant; HNM, hepatic neoplasms malignant; ROR, reporting odds ratio; CI, confidence interval.</div>

Journal of Clinical Pharmacy and Therapeutics

fig3

Figure 3

Figure 3: Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System 

Figure 3 | Digestive Tract Cancer-Related Adverse Events Correlated with Proton Pump Inhibitors Use: A Pharmacovigilance Study of the FDA Adverse Event Reporting System 